Keywords: Vernalis, Frovatriptan, Migraine, Liceninsg, Placing, Isogenica, MRSA

Vernalis to re-acquire EU frovatriptan royalties; Isogenica gains rights to commercialize drugs with MRSA potential

Article | 15 February 2010

Print This

UK biotechnology firm Vernalis has announced the placing of £30 million ($46.3 million) in new shares to fund the reacquisition of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in